Inhibikase Therapeutics, Inc. Notes Payable
Inhibikase Therapeutics, Inc. (IKT) had Notes Payable of $0 as of 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Balance Sheet › Liabilities
us-gaap:NotesPayable · last filed 2025-03-27
- 2024-12-31: Notes Payable $0.00.
- 2023-12-31: Notes Payable $381.78K.
- 2022-12-31: Notes Payable $0.00.
- 2021-12-31: Notes Payable $248.91K.
| Period end | Notes Payable |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-27 |
| 2023-12-31 | $381.78K 10-K · filed 2025-03-27 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-27 |
| 2021-12-31 | $248.91K 10-K · filed 2022-03-31 |
| 2021-09-30 | $248.91K 10-Q · filed 2021-11-15 |
| 2021-06-30 | $248.91K 10-Q · filed 2021-08-16 |
| 2021-03-31 | $1.24M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $319.00K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |